Connect with us

BUSINESS

Lexaria Bioscience Corp (NASDAQ: LEXX) Release HYPER-H12-1 Study Results And Avails DehydraTECH in The US

Published

on

Lexaria Bioscience Corp (NASDAQ: LEXX) has released partial results from HYPER-H12-1 human clinical trial evaluating DehhydraTech processed CBD as a potential hypertension application. Partial results linked to blood pressure were releases with additional BP subset data analyses, including pharmacokinetics expected once complete. 

Lexaria was encouraged by DehydraTECH results 

Chris Bunka, Lexaria CEO, said, “We are very encouraged by these early results in our 2021 hypertension program. Lexaria’s technology enabled a rapid and sustained drop in blood pressure, especially systolic pressure and particularly in Stage 2 hypertensive volunteers.”

Lead investigator Phil Ainslie said, “These early results are extremely promising in this at-risk hypertensive population and provide a fundamental support for expansion into more prolonged repeat dosing and future longer term clinical trial.”

Both female and male volunteers had lower blood pressure, which was most noticeable with DehydraTECH-CBD in the first 10-50 minutes of the research, confirming previous findings that DehydraTECH outperforms generic CBD controls.

DehydraTECH is available in 7, 000 stores in the US

The company has announced that consumers are embracing the DehydraTECH technology, and it’s available in 7,000 stores in the US. Bunka said, “Lexaria’s technology is enabling increased market share and sales growth for our continually growing list of corporate clients. We are delighted to help these innovators of today and leaders of tomorrow offer their clients superior performance and experiences that competitors simply cannot match, and we are highly anticipatory of additional growth to come.”

Lexaria sought opinions of corporate clients regarding DehydraTECH experiences. Cannadips President Case Mandal said, “Cannadips is the original tobacco-free and nicotine-free CBD pouch and we pride our Humboldt County traditions of innovation and continual technological evolution to help consumers nationwide enjoy superior dip experiences. We scoured the market for the best technology to put into our products and DehydraTECH was, hands down, the most palatable and efficacious delivery system for our CBD products.”

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

BUSINESS

Choom Holdings Inc. (OTCMKTS: CHOOF) Expanding Operations With More Locations As It Settles Debt

Published

on

Choom Holdings Inc. (OTCMKTS: CHOOF) has provided a mid-year 2021 operational updates in which several initiatives were commenced. 

Choom Holdings continues to expand with opening ore locations 

The company opened the Liberty Village location in Toronto on July 28 as part of its efforts to expand. The location is the first flagship location in Toronto. In Hamilton the company broke ground for the construction of its next location in Ontario. So far the twelve-week construction timeline is almost 50% to completion and opening is expected in early fall. Pre-construction activities are underway in Ottawa for the Choom’s next Ontario location and in Vancouver the company completed Dunsmuir Street location acquisition on July 1. Also, pre-construction efforts are underway at the British Columbia location. 

CEO Corey Gillon said, “As we move through the summer months, the strengthening of the business continues.. Our mission remains the same in providing the best retail cannabis experience in every market we serve. As the economy begins to re-open, so to do our stores, and we look forward to the opportunity to further serve our growing customer base.”

The company has also announced the engagement of Stockhouse Publishing Ltd. to offer enhanced marketing awareness and ad services for a period of 2 months from July 2021. The company agreed a cash fee of around $100,000 during the period of the contract.

Choom enters agreement to settle debt

The company announced the signing if a settlement agreement with a debtholder. According to the agreement Choom will settle debt obligations of around $550,000 in consideration of extinguishment of around $875,00 owed by the debtholder and issuance of around 3.175 million Choom common shares at $0.063 per share. Most importantly, Choom shares will be issued in satisfaction to the Debt and will be subject to a four month statutory hold with an expiry of December 12 2021. 

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

TILT Holdings Inc. (OTCMKTS: TLLTF) Receives Adult Use License In Massachusetts and Enters License Agreement With 1906

Published

on

TILT Holdings Inc. (OTCMKTS: TLLTF) has announced that its subsidiary Commonwealth Alternative Care Inc. ha received four provisional licenses from Massachusetts Cannabis Control Commission  for growing, manufacture and sale of adult use recreational cannabis at the Taunton location and sale of adult use cannabis to the Brockton location. Equally the commission issued the subsidiary with a final license for medical cannabis sale in Brockton. 

CAC receives licenses for Brockton location 

CAC received provisional Retail Establishment and Medical Dispensary license for the fully constructed Brockton facility located at 1090 W Chestnut Street. The company is expected to hpst a job fair at the location and expects the location to open for busi8enss in the coming weeks after CCC’s final inspection. 

TILT Holdings CEO Gary Santo said, “Our Taunton facility has been supplying cannabis retailers and medical marijuana patients in Massachusetts with premium cannabis products for nearly three years while we awaited approval of our remaining submitted license applications. Along the way, we expanded our cultivation capacity, partnered with some of the most recognizable brands in the industry and continued to expand our wholesale reach to be ready for this moment. The approval of these provisional licenses, along with the final approval of our Brockton medical license, will further expand CAC’s presence in the state.”

TILT enters distribution agreement with 1906

Recently TILT announced a multi-state licensing agreement with 1906 for manufacture and distribution of its rapid onset cannabis products. 1906 is a cannabis products innovator that creates highly functional formulations combining moderately dosed marijuana with select plant medicines. 

TILT will through its Standard  Farms Ohio, LLC, Standard farms, LLC in Pennsylvania and Commonwealth Alternative Care Inc. in Massachusetts offer full service, packaging, wholesale manufacturing and distribution services to expedite 1906’s non-smokeable cannabis products’ availability to patients  in the medical and adult use markets it serves. TILT will launch a 1906 line of chocolates in Massachusetts and 1906 drops in Ohio and Pennsylvania. 

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

SOL Global Investments Corp (OTCMKTS: SOLCF) Issues Corporate Update And Announce Settlement With 1235 Fund LP

Published

on

SOL Global Investments Corp (OTCMKTS: SOLCF) has announced that it will continue buying shares  under the normal course issuer bid (NCIB) previously announced in March 31, 2021. 

So far the company has purchased around 1.539 million common shares during the current purchase cycle as per the NCIB at a [rice of $4.3831 per share. As per the NCIB, the company may purchase a maximum of 2.738 million common shares that represent around 5% of SOL Global Investments’ outstanding and issued common shares as of the announcement time of the NCIB. The NCIB will terminate in March 31 next year or ealyr at the discretion of the company. 

SOL Global makes board appointments

The company also announced the addition of Kevin Taylor and Alex Spiro to its Board of Directors. Following their appointment Taylor will be the chairperson of the Compensation Committee while Spiro will be the Chairman of the Compliance Committee.

CEO Andy DeFrancesco said, “Thanks to our turbocharged success we have put ourselves in a position to bulk up, and that starts up top at the board level. It’s incredible for us to have Alex and Kevin joining our board. They both have outstanding track records and are leaders in their respective positions. Their experience will augment the team and I in our push for performance and top tier stockholder growth.” 

SOL Global settles suit connected to debenture 

Recently the company announced the settlement of a litigation in connection to senior, secured non-convertible  debenture offered and issued to 1235 Fund LP  in amount of CA$50 million and carrying an interest of 6% per year. The company had previously disclosed that it had commenced legal proceedings against 1235 in New York concern the Debenture interpretation and associated arrangement and rights under the agreements. 

According to  the agreement, SOL Global’s subsidiary will acquire all 1235 rights under the debenture for CA$120 million which will be paid in September 7, 2021.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

Trending Stories